At 5.2% CAGR, the Europe Cerebrospinal Fluid Management Market is projected to be worth US$ 817.12 million by 2030, says Business Market Insights

According to Business Market Insights’ research, the Europe cerebrospinal fluid management market was valued at US$ 544.31 million in 2022 and is expected to reach US$ 817.12 million by 2030, registering a CAGR of 5.2% from 2022 to 2030. Increasing cases of cerebrospinal fluid leak is the critical factors attributed to the Europe cerebrospinal fluid management market expansion.             

CSF parameters are extensively evaluated as biomarkers of neurological disorders in adult patients. Circulating microRNAs in CSF are a promising class of biomarkers for the diagnosis of various neurological diseases. Neurological disorders such as Parkinson’s Disease (PD), Alzheimer’s Disease (AD), epilepsy, and seizures often lead to altered CSF parameters. According to an article published in Nature, 76 CSF proteins were found to be structurally altered in patients that were diagnosed with PD when compared to normal individuals. The study also suggests that these CSF proteins can be used as biomarkers for the diagnosis or treatment of the disease. PD is a neurodegenerative disease associated with loss of cognitive impairment and motor function. According to the World Health Organization (WHO) report published in 2022, the prevalence of PD has doubled in the last 25 years, affecting ~1% of the global population aged more than 60 years. Similarly, a few of the CSF parameters such as protein and lactate levels are altered in patients suffering from seizure or status epilepticus. Therefore, various R&D activities are going on for using CSF parameters in the treatment of seizures or epilepsy. Further, despite the availability of various CSF assays for the detection of Alzheimer’s disease using CSF in the market, there are unmet needs for biomarkers for detection and treatment purposes. As the detection of cases of Alzheimer’s disease and PD increases, there is increase in demand for CSF management devices as the cases of CSF leaks may increases. Therefore, a rise in the prevalence of neurological disorders is fueling the research and development activities for the use of CSF management products in the treatment of these disorders.

On the contrary, risk of failure and malfunctioning hampers on the growth of Europe cerebrospinal fluid management market. 

Based on product, the Europe cerebrospinal fluid management market is bifurcated into CSF shunts and CSF drainage systems. The CSF shunts segment held 87.3% share of Europe cerebrospinal fluid management market in 2022, amassing US$ 475.38 million. It is projected to garner US$ 724.31 million by 2030 to expand at 5.4% CAGR during 2022–2030.

Based on end user, the Europe cerebrospinal fluid management market is segmented into hospitals, clinics, ambulatory surgical centers, and others. The hospitals segment held 56.8% share of Europe cerebrospinal fluid management market in 2022, amassing US$ 309.39 million. It is projected to garner US$ 479.02 million by 2030 to expand at 5.6% CAGR during 2022–2030.

Based on country, the Europe cerebrospinal fluid management market has been categorized into the U.K., Germany, France, Italy, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 24.9% share of Europe cerebrospinal fluid management market in 2022. It was assessed at US$ 135.55 million in 2022 and is likely to hit US$ 209.26 million by 2030, exhibiting a CAGR of 5.6% during 2022–2030.            

Key players operating in the Europe cerebrospinal fluid management market are Argi Group Health Services Ltd Sti, B. Braun SE, Delta Surgical Ltd, Integra LifeSciences Holdings Corp, Medtronic Plc, Moller Medical GmbH, Natus Medical Inc, Sophysa SA, and Spiegelberg GmbH & Co KG, among others.

• In 2023, The Möller Medical GmbH had recalled some of a lot of Drainage Set LiquoGuard 7 as leakage was detected in the course of use in isolated cases as part of its ongoing quality and market monitoring processes.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com